Emerald Mutual Fund Advisers Trust Buys 64,677 Shares of Lumexa Imaging Holdings, Inc. $LMRI

Posted by George Bondi on Jul 14th, 2026

Emerald Mutual Fund Advisers Trust increased its holdings in shares of Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI – Free Report) by 11.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 653,342 shares of the company’s stock after acquiring an additional 64,677 shares during the quarter. Emerald Mutual Fund Advisers Trust’s holdings in Lumexa Imaging were worth $5,619,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Assetmark Inc. bought a new stake in Lumexa Imaging during the fourth quarter valued at approximately $36,000. Strs Ohio bought a new position in shares of Lumexa Imaging in the first quarter worth approximately $38,000. Barclays PLC bought a new position in Lumexa Imaging during the 4th quarter valued at about $133,000. Sandia Investment Management LP purchased a new stake in Lumexa Imaging during the fourth quarter valued at $185,000. Finally, Hudson Bay Capital Management LP purchased a new stake in Lumexa Imaging during the fourth quarter valued at approximately $237,000.

Lumexa Imaging Stock Down 7.1%

Lumexa Imaging stock opened at $11.15 on Tuesday. The company has a debt-to-equity ratio of 1.43, a current ratio of 1.40 and a quick ratio of 1.40. Lumexa Imaging Holdings, Inc. has a 52-week low of $6.45 and a 52-week high of $19.45. The business’s fifty day simple moving average is $9.48. The stock has a market capitalization of $1.07 billion and a price-to-earnings ratio of -18.90.

Insider Activity

In other news, Director Brett Brodnax purchased 35,000 shares of Lumexa Imaging stock in a transaction dated Tuesday, May 19th. The shares were purchased at an average price of $7.25 per share, with a total value of $253,750.00. Following the transaction, the director owned 62,027 shares in the company, valued at $449,695.75. This represents a 129.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on LMRI shares. Wall Street Zen raised shares of Lumexa Imaging from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. Barclays reduced their target price on shares of Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating for the company in a report on Wednesday, May 20th. Finally, Weiss Ratings raised shares of Lumexa Imaging from a “sell (e)” rating to a “sell (d)” rating in a report on Thursday, June 25th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $16.00.

View Our Latest Analysis on LMRI

Lumexa Imaging Company Profile

(Free Report)

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).